UB Paderborn / Katalog / Suche / in CDI

A Phase 2 Trial of Guselkumab versus Adalimumab for Plaque Psoriasis

The New England journal of medicine, 2015-07, Vol.373 (2), p.136-144

2015

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator–controlled VOYAGE 1 trial

Journal of the American Academy of Dermatology, 2017-03, Vol.76 (3), p.405-417

2017

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator–controlled VOYAGE 2 trial

Journal of the American Academy of Dermatology, 2017-03, Vol.76 (3), p.418-431

2017

Link zum Volltext

Verfügbarkeit prüfen

Guselkumab (an IL-23–specific mAb) demonstrates clinical and molecular response in patients with moderate-to-severe psoriasis

Journal of allergy and clinical immunology, 2014-04, Vol.133 (4), p.1032-1040

2014

Link zum Volltext

Verfügbarkeit prüfen

Genome-wide association study identifies multiple HLA loci for sarcoidosis susceptibility

Human molecular genetics, 2023-08, Vol.32 (16), p.2669-2678

2023

Link zum Volltext

Verfügbarkeit prüfen

Validation of psychometric properties and development of response criteria for the psoriasis symptoms and signs diary (PSSD): results from a phase 3 clinical trial

The Journal of dermatological treatment, 2019-01, Vol.30 (1), p.27-34

2019

Link zum Volltext

Verfügbarkeit prüfen

P021: Long-term follow-up of cipaglucosidase alfa/miglustat in ambulatory and non-ambulatory patients with Pompe disease: An open-label phase I/II study (ATB200-02)

Genetics in Medicine Open, 2023, Vol.1 (1), p.100031, Article 100031

2023

Link zum Volltext

Verfügbarkeit prüfen

A New Tool To Assess Sarcoidosis Severity

Chest, 2006-05, Vol.129 (5), p.1234-1245

2006

Link zum Volltext

Verfügbarkeit prüfen

The efficacy and tolerability of MK-0633, a 5-lipoxygenase inhibitor, in chronic asthma

Respiratory medicine, 2012-01, Vol.106 (1), p.34-46

2012

Link zum Volltext

Verfügbarkeit prüfen

A 45-Year-Old Man With Severe Dysphagia and Pulmonary Infiltrates

Chest, 2007-04, Vol.131 (4), p.1256-1259

2007

Link zum Volltext

Verfügbarkeit prüfen

Onset and duration of attenuation of exercise-induced bronchoconstriction in children by single-dose of montelukast

Allergy and asthma proceedings, 2011-11, Vol.32 (6), p.453

2011

Link zum Volltext

Verfügbarkeit prüfen

Plasma total GAA protein PK profiles differ between cipaglucosidase alfa/miglustat and alglucosidase alfa

Molecular genetics and metabolism, 2022-02, Vol.135 (2), p.S63-S63

2022

Link zum Volltext

Verfügbarkeit prüfen

Population Pharmacokinetic Modeling of Guselkumab, a Human IgG1λ Monoclonal Antibody Targeting IL‐23, in Patients with Moderate to Severe Plaque Psoriasis

Journal of clinical pharmacology, 2018-05, Vol.58 (5), p.613-627

2018

Link zum Volltext

Verfügbarkeit prüfen

Effect size analysis of cipaglucosidase alfa plus miglustat versus alglucosidase alfa in ERT-experienced adults with late-onset Pompe disease in PROPEL

Molecular genetics and metabolism, 2024-02, Vol.141 (2), p.107971, Article 107971

2024

Link zum Volltext

Verfügbarkeit prüfen

Long-term follow-up of cipaglucosidase alfa/miglustat in ambulatory patients with Pompe disease: An open-label phase I/II study (ATB200-02)

Molecular genetics and metabolism, 2023-02, Vol.138 (2), p.107042, Article 107042

2023

Link zum Volltext

Verfügbarkeit prüfen

104-week efficacy and safety of cipaglucosidase alfa plus miglustat in adults with late-onset Pompe disease: a phase III open-label extension study (ATB200-07)

Journal of neurology, 2024-05, Vol.271 (5), p.2810-2823

2024

Link zum Volltext

Verfügbarkeit prüfen

Information contributed by meta-analysis in exposure–response modeling: application to phase 2 dose selection of guselkumab in patients with moderate-to-severe psoriasis

Journal of pharmacokinetics and pharmacodynamics, 2014-06, Vol.41 (3), p.239-250

2014

Link zum Volltext

Verfügbarkeit prüfen

An update on the long-term safety experience of ustekinumab: results from the psoriasis clinical development program with up to four years of follow-up

Journal of drugs in dermatology, 2012-03, Vol.11 (3), p.300

2012

Link zum Volltext

Verfügbarkeit prüfen

Two cases of hepatitis B in patients with moderate to severe psoriasis with ustekinumab

Journal of drugs in dermatology, 2012-12, Vol.11 (12), p.1498

2012

Link zum Volltext

Verfügbarkeit prüfen

The presence of hospitalists in medical education

Academic medicine, 2000-10, Vol.75 (10 Suppl), p.S34-S36

2000

Link zum Volltext

Verfügbarkeit prüfen

Sarcoidosis

Diffuse Parenchymal Lung Disease, 2007, Vol.36, p.127-138

2007

Link zum Volltext

Verfügbarkeit prüfen

Apoptosis-related genetic polymorphisms in sarcoidosis

Wasfi, Yasmine S

2005

Link zum Volltext
ProQuest

Menü

Weitere Dienste

Einstellungen

A Phase 2 Trial of Guselkumab versus Adalimumab for Plaque Psoriasis

Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator–controlled VOYAGE 1 trial

Guselkumab (an IL-23–specific mAb) demonstrates clinical and molecular response in patients with moderate-to-severe psoriasis

Genome-wide association study identifies multiple HLA loci for sarcoidosis susceptibility

Validation of psychometric properties and development of response criteria for the psoriasis symptoms and signs diary (PSSD): results from a phase 3 clinical trial

P021: Long-term follow-up of cipaglucosidase alfa/miglustat in ambulatory and non-ambulatory patients with Pompe disease: An open-label phase I/II study (ATB200-02)

A New Tool To Assess Sarcoidosis Severity

The efficacy and tolerability of MK-0633, a 5-lipoxygenase inhibitor, in chronic asthma

A 45-Year-Old Man With Severe Dysphagia and Pulmonary Infiltrates

Onset and duration of attenuation of exercise-induced bronchoconstriction in children by single-dose of montelukast

Plasma total GAA protein PK profiles differ between cipaglucosidase alfa/miglustat and alglucosidase alfa

Population Pharmacokinetic Modeling of Guselkumab, a Human IgG1λ Monoclonal Antibody Targeting IL‐23, in Patients with Moderate to Severe Plaque Psoriasis

Effect size analysis of cipaglucosidase alfa plus miglustat versus alglucosidase alfa in ERT-experienced adults with late-onset Pompe disease in PROPEL

Long-term follow-up of cipaglucosidase alfa/miglustat in ambulatory patients with Pompe disease: An open-label phase I/II study (ATB200-02)

104-week efficacy and safety of cipaglucosidase alfa plus miglustat in adults with late-onset Pompe disease: a phase III open-label extension study (ATB200-07)

Information contributed by meta-analysis in exposure–response modeling: application to phase 2 dose selection of guselkumab in patients with moderate-to-severe psoriasis

An update on the long-term safety experience of ustekinumab: results from the psoriasis clinical development program with up to four years of follow-up

Two cases of hepatitis B in patients with moderate to severe psoriasis with ustekinumab

The presence of hospitalists in medical education

Sarcoidosis

Apoptosis-related genetic polymorphisms in sarcoidosis

Suchergebnisse filtern